Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients

Annals of Hematology

Volumn 87, Issue 9, 2008, Pages 727-734

  Gill, Saar ^a   Lane, Steven W ^b   Crawford, Julie ^c   Cull, Gavin ^c   Joske, David ^c   Marlton, Paula ^b   Mollee, Peter N ^b   Prince, H Miles ^a,d   Seymour, John F ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Hyper CVAD; Therapy related acute myeloid leukaemia; Therapy related myelodysplasia

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW BIOPSY; CELL DAMAGE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPENIA; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PANCYTOPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TIME FACTORS; VINCRISTINE;

EID: 48649106035     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0488-6     Document Type: Article

References (30)

1. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M (1997) The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic lymphoma. Leukemia 11:2039-2044
2. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreef M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547-561
3. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ (2004) Long-term doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensiveregimen, in adult acute lymphoblastic leukemia. Cancer 101:2788-2801
4. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarian H (2004) Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624-1630
5. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470
6. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580
7. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809
8. Romaguera JE, Fayad L, Rodriguez M, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023
9. Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, Szer J, Prince HM (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 86:101-105
10. Shapiro M, Wasik MA, Junkins-Hopkins JM, Rook AH, Vittorio CC, Itakura H, Frankel MC, Georgala S, Schuster SJ (2003) Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol 74:46-51 (S-Plus 2000 User's Guide, Data Analysis Products Division, MathSoft, Seattle, WA)
11. Keane C, Gibbs S, Seymour JF, Mills AK, Grimmett K, Van Kuilenberg R, Saal R, Gill D, Prince HM, Marlton P, Mollee P (2006) The hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilise peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilisation. Hematol Oncol 24:159-163
12. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21:897-906
13. Smith SM, Le Beau MM, Hou D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102:43-52
14. Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273-3279
15. Lenz G, Dreyling M, Scheignitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective trial of the German low grade lymphoma study group. J Clin Oncol 22:4926-4933
16. Pedersen-Bjergaard J (2005) Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 352:1591-1594
17. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA, Rohatiner AZ (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955
18. Cancer Council Victoria. Clinical trials reference information. Available from: http://www.cancervic.org.au/trials/details.asp?ContentID= nhl11 (accessed April 22, 2007)
19. Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN (2006) Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma 47:1813-1817
20. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 1st edn. IARC, Lyon
21. Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data, 2nd edn. Wiley, Hoboken, New Jersey
22. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346
23. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F (2003) Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 121:913-918
24. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Corlenghi E, Ungari M, Ruggeri G, Rossi G (2006) Delayed-onset peripheral blood cytopenias after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 47:1013-1017
25. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding M, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195-200
26. Gomez GA, Aggarwal KK, Han T (1982) Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma. Cancer 50:2285-2288
27. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B (2006) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604-3610
28. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman A (1999) Outcome in patients with myelodysplasic syndrome after autologous marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17:3128-3135
29. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA (1991) Treatment of adult acute lymphoblastic leukaemia with intensive cyclical chemotherapy: A follow-up report. Blood 78:2814-2822
30. Linker C, Damon L, Ries C, Navarro W (2002) Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukaemia. J Clin Oncol 20:2464-2471